World's first protective antibodies against Marburg virus developed

31-Mar-2017 - Germany

A team of scientists around Professor Michael Hust from the Institute of biochemistry, biotechnology and bioinformatics of the Technische Universität Braunschweig developed successfully a panel of antibodies against highly-pathogenic Marburg virus. These are the worldwide first recombinant antibodies which are protective in an animal model against the infection with wildtype Marburg virus. Together with colleagues in France and in the US, the scientists of the TU Braunschweig used the antibody phage display technology to generate these antibodies.

"We are happy, that we could contribute to the worldwide first recombinant protective antibodies against Marburg virus using our antibody phage display technology. We hope, that these antibodies will be developed as therapeutic in the future“, says project leader Prof. Dr. Michael Hust from the Institute of Biochemistry, Biotechnology and Bioinformatics of the TU Braunschweig. Dr. Sebastian Miethe adds: “The development of these antibodies was only possible in close cooperation with our partners in France and USA. These long lasting cooperation was also successful in other projects focused on pathogens and toxins.“

Original publication

Other news from the department science

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous